Skip to content

Discontinued — last reported Q4 '19

Interest Income at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$22.56M+18.7%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$6M-14.3%
XER
Xeris Biopharma Holdings, Inc.XERS
$1.2M+2.3%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$5.35M-31.5%
Arrowhead Research logo
Arrowhead ResearchARWR
$16.87M+75.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$6.25M+16.0%

Segments

By segment

See full
Reportable Segment$2.18M+204%

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$782.09M+58.2%
Enterprise value$687.64M+32.5%
P/E6.3×
P/S6.4×-5.8×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.

The official record: Zevra Therapeutics, Inc.’s 10-K, filed February 28, 2020, on SEC EDGAR. View the filing →

Questions, answered.

What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.